The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
High-dose osimertinib for CNS progression in EGFR+ non-small cell lung cancer (NSCLC): A multi-institutional experience.
 
Andrew Piper-Vallillo
No Relationships to Disclose
 
Julia K Rotow
Honoraria - Takeda
Consulting or Advisory Role - AstraZeneca
Travel, Accommodations, Expenses - Array BioPharma; Lilly
 
Jacqueline V Aredo
No Relationships to Disclose
 
Khvaramza Shaverdashvili
No Relationships to Disclose
 
Jia Luo
No Relationships to Disclose
 
Jennifer W Carlisle
No Relationships to Disclose
 
Hatim Husain
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Foundation Medicine; Takeda
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Merck
 
Alona Muzikansky
Consulting or Advisory Role - Sofregen
 
Rebecca Suk Heist
Honoraria - Chugai/Roche
Consulting or Advisory Role - Apollomics; Boehringer Ingelheim; Novartis; Tarveda Therapeutics
Research Funding - Abbvie (Inst); Agios (Inst); Celgene (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); Exelixis (Inst); Exelixis (Inst); Incyte (Inst); Lilly (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Peregrine Pharmaceuticals (Inst); Pfizer (Inst); Pfizer (Inst); Roche (Inst); Turning Point Therapeutics (Inst)
 
Deepa Rangachari
Consulting or Advisory Role - Advance Medical; DynaMed
Research Funding - Abbvie/Stemcentrx; Bristol-Myers Squibb; Novocure
 
Suresh S. Ramalingam
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Lilly/ImClone; Loxo; Merck; Nektar; Takeda; Tesaro
Research Funding - Abbvie (Inst); Advaxis (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genmab (Inst); Merck (Inst); Merck (Inst); Pfizer (Inst); Takeda (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Heather A. Wakelee
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Helsinn Therapeutics; Janssen Oncology; Mirati Therapeutics; Xcovery
Research Funding - ACEA Biosciences (Inst); Arrys Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Merck (Inst); Novartis (Inst); Pharmacyclics (Inst); Xcovery (Inst)
Travel, Accommodations, Expenses - AstraZeneca
(OPTIONAL) Uncompensated Relationships - Genentech/Roche; Merck; Takeda
 
Helena Alexandra Yu
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Lilly
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Lilly
Other Relationship - Astellas Pharma
 
Lecia V. Sequist
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Genentech/Roche; Janssen Oncology; Merrimack
Research Funding - AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Genentech (Inst); Guardant Health (Inst); Incyte (Inst); Johnson & Johnson (Inst); Loxo (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); Pfizer (Inst)
 
Joshua Bauml
Consulting or Advisory Role - AstraZeneca; Ayala Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech; Guardant Health; Janssen; Merck; Novartis; Regeneron; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Carevive Systems (Inst); Incyte (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Takeda (Inst)
 
Joel W. Neal
Honoraria - Biomedical Learning Institute; CME Matters; Medscape; MJH Life Sciences; MLI Peerview; Prime Oncology; Research to Practice; Rockpointe
Consulting or Advisory Role - AstraZeneca; Calithera Biosciences; Exelixis; Genentech/Roche; Jounce Therapeutics; Lilly; Takeda
Research Funding - Adaptimmune (Inst); Boehringer Ingelheim (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Up To Date - Royalties
 
Zofia Piotrowska
Consulting or Advisory Role - AstraZeneca; Genentech; Guardant Health; Immunogen; Incyte; Lilly; Medtronic; Spectrum Pharmaceuticals
Research Funding - ARIAD/Takeda (Inst); AstraZeneca (Inst); Guardant Health (Inst); Johnson & Johnson (Inst); Novartis (Inst); Spectrum Pharmaceuticals (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - ARIAD/Takeda; AstraZeneca; Genentech